FIELD: biotechnology.
SUBSTANCE: antibody to ICAM-1 or its antigen-binding fragment are proposed. Nucleic acid molecules encoding the specified antibody, a recombinant expression vector, and a recombinant cell for the production of an antibody according to the invention are also proposed. In addition, a pharmaceutical composition for the prevention or treatment of a disease mediated with immune cells, as well as a composition for detection of ICAM-1 are provided. Compositions contain an antibody to ICAM-1 or its antigen-binding fragment as an active ingredient.
EFFECT: invention provides regulation of differentiation and function of dendritic cells for more efficient control of an immune response.
14 cl, 39 dwg, 11 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
ANTI-ApoC3 ANTIBODIES AND METHODS FOR THEIR USE | 2018 |
|
RU2781074C2 |
IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
CD8A-BINDING DOMAINS OF III FIBRONECTIN TYPE | 2017 |
|
RU2759952C2 |
Authors
Dates
2023-02-09—Published
2019-12-31—Filed